After eight years, Macro Polo has ceased operations as the Paulson Institute will focus its independent research on supporting its programs as it continues to diversify its scope.
We appreciate the community that has grown around Macro Polo and the fruitful engagement we’ve had with our legion of smart and sharp audience. You’ve pushed us to deliver even more original work and innovative products. Our body of work speaks for itself, and we hope it will have a long shelf life – that was the intent from MP’s inception.
MP’s website is now archived and no new work will be published henceforth on this site. Please visit www.paulsoninstitute.org for future research and policy work on a range of global issues.
Thank you all for the support over the years, it has been a privilege to have had a home at the Paulson Institute and to have built it the way we did.
- Team Macro Polo
As the world’s second-largest healthcare market, China spends about $575 billion a year on the sector, roughly equivalent to Sweden’s GDP. But because of China’s large population, that translates into only $420 in per capita healthcare spending, just 4% of what an average American spends. This healthcare supply shortage is exacerbated by rising demand from wealthier Chinese who seek quality care, better insurance, and diverse services.
On the regulatory side, the Chinese government continues to reform the healthcare sector by allowing doctors to work
outside the public hospital system, encouraging the privatization of hospitals, and expanding public healthcare insurance to cover private hospitals.
The significant mismatch between supply and demand, coupled with policy changes to support the sector, have incentivized private investment to flock into areas ranging from advanced pharmaceuticals and medical devices to primary care clinics, elderly care, and insurance products.
Shandong Sinobioway Biomedicine is a pharmaceutical company. It manufactures biopharmaceuticals and chemical intermediaries. Its flagship product NOBEX is used for treating nerve system syndromes. The company distributes its products both in the China market and globally, including in the United States, Brazil, Canada, India, Japan, and South Korea.
Pan Aihua
Zibo, Shandong
(010) 8289.0086
baoy333@163.com
Shandong Sinobioway's parent, Beijing Sinobioway Group, entered into a collaborative venture in 2015 with California-based biotech firm BioAtla to develop and commercialize Conditionally Active Biologic antibody therapeutics. As of today, the parent group has poured more than $100 million into BioAtla, in the form of contract payments and equity investment.